Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.

@article{Winston2003IntravenousAO,
  title={Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.},
  author={Drew J. Winston and Richard T Maziarz and Pranatharthi Chandrasekar and Hillard M Lazarus and Mitchell H. Goldman and Jeffrey L. Blumer and Gerhard J Leitz and Mary C. Territo},
  journal={Annals of internal medicine},
  year={2003},
  volume={138 9},
  pages={705-13}
}
BACKGROUND Allogeneic hematopoietic stem-cell transplant recipients often receive fluconazole or an amphotericin B preparation for antifungal prophylaxis. Because of concerns about fungal resistance with fluconazole and toxicity with amphotericin B, alternative prophylactic regimens have become necessary. OBJECTIVE To compare the efficacy and safety of intravenous and oral itraconazole with the efficacy and safety of intravenous and oral fluconazole for long-term prophylaxis of fungal… CONTINUE READING